The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: T-cell binding fusion peptides. Buy the report here.
Smarter leaders trust GlobalData
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
80+ innovations will shape the pharmaceutical industry
See Also:
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
T-cell binding fusion peptides is a key innovation area in the pharmaceutical industry
T-cell binding fusion peptides are a type of synthetic or engineered peptide that are designed to interact with T cells, a type of immune cell involved in the adaptive immune response. T-cell binding fusion peptides are composed of amino acids, just like natural proteins and peptides. They are often engineered to include sequences that mimic or resemble antigens or epitopes recognized by T cells. The design may also include additional sequences or motifs that enhance binding to TCRs. These peptides are typically created to have specific binding affinity for T-cell receptors (TCRs) and are used in various applications, primarily in the field of immunotherapy and vaccine development.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of T-cell binding fusion peptides.
Key players in T-cell binding fusion peptides – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to T-cell binding fusion peptides
| Company | Total patents (2010 - 2022) | Premium intelligence on the world's largest companies |
| Immatics | 305 | Unlock Company Profile |
| Bristol-Myers Squibb | 71 | Unlock Company Profile |
| Fate Therapeutics | 69 | Unlock Company Profile |
| CARsgen Therapeutics | 59 | Unlock Company Profile |
| Cellectis | 49 | Unlock Company Profile |
| Precision Biosciences | 44 | Unlock Company Profile |
| EXUMA Biotech | 43 | Unlock Company Profile |
| CRISPR Therapeutics | 43 | Unlock Company Profile |
| Novartis | 40 | Unlock Company Profile |
| Editas Medicine | 34 | Unlock Company Profile |
| Memorial Sloan Kettering Cancer Center | 32 | Unlock Company Profile |
| Intellia Therapeutics | 29 | Unlock Company Profile |
| bluebird bio | 25 | Unlock Company Profile |
| NantWorks | 17 | Unlock Company Profile |
| F. Hoffmann-La Roche | 15 | Unlock Company Profile |
| Gilead Sciences | 12 | Unlock Company Profile |
| IO Biosciences | 11 | Unlock Company Profile |
| Sangamo Therapeutics | 11 | Unlock Company Profile |
| Etubics | 10 | Unlock Company Profile |
| DRK-Blutspendedienst Baden-Wurttemberg-Hessen | 10 | Unlock Company Profile |
| Sorrento Therapeutics | 8 | Unlock Company Profile |
| Fujifilm | 8 | Unlock Company Profile |
| Bayer | 6 | Unlock Company Profile |
| Abcyte Therapeutics | 5 | Unlock Company Profile |
| 2Seventy Bio | 5 | Unlock Company Profile |
| Georg-Speyer-Haus | 5 | Unlock Company Profile |
| Fortress Biotech | 5 | Unlock Company Profile |
| Cartherics | 4 | Unlock Company Profile |
| Shanghai Cell Therapy Group | 4 | Unlock Company Profile |
| Autolus | 4 | Unlock Company Profile |
| Asclepius Technology Group Suzhou | 4 | Unlock Company Profile |
| ProvIncial Health Services Authority | 4 | Unlock Company Profile |
| General Hospital | 4 | Unlock Company Profile |
| KSQ Therapeutics | 3 | Unlock Company Profile |
| F1 Oncology Sezc | 2 | Unlock Company Profile |
| Shanghai Yijie Biotechnology | 2 | Unlock Company Profile |
| Obsidian Therapeutics | 2 | Unlock Company Profile |
| CBMG | 2 | Unlock Company Profile |
| Innovative Cellular Therapeutics | 2 | Unlock Company Profile |
| NEW HOPE, CITY OF | 2 | Unlock Company Profile |
| Humanigen | 2 | Unlock Company Profile |
| Noile-Immune Biotech | 1 | Unlock Company Profile |
| TCR2 Therapeutics | 1 | Unlock Company Profile |
| Aleta Biotherapeutics | 1 | Unlock Company Profile |
| NeoImmuneTech | 1 | Unlock Company Profile |
| A2 Biotherapeutics | 1 | Unlock Company Profile |
| Poseida Therapeutics | 1 | Unlock Company Profile |
| Huadong Medicine | 1 | Unlock Company Profile |
| BioAtla | 1 | Unlock Company Profile |
| Nationwide Children's Hospital | 1 | Unlock Company Profile |
Source: GlobalData Patent Analytics
Immatics is one of the leading patent filers in T-cell binding fusion peptides. Immatics is a clinical-stage biopharmaceutical company that specializes in the development of innovative immunotherapies for the treatment of cancer. The company's focus is on harnessing the power of the immune system, particularly T cells, to target and eliminate cancer cells. Immatics is known for its focus on T-cell receptor (TCR) therapies, cancer vaccines, and other immunotherapeutic approaches. Bristol-Myers Squibb (BMS) and Fate Therapeutics are some of the other key patent filers in T-cell binding fusion peptides.
In terms of application diversity, Fujifilm leads the pack, while Provincial Health Services Authority and Autolus stood in second and third positions, respectively. By means of geographic reach, Immatics held the top position followed by F. Hoffmann-La Roche and Precision Biosciences.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
